Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, Phase 1/2, multicenter study to evaluate the safety,
tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal
antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody
(AGEN2034), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid
tumors. This study will also determine the RP2D of AGEN1181 monotherapy and in combination
with AGEN2034.